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Abstract 
Introduction 
Eosinophilic granulomatosis with polyangiitis is a rare and potentially fatal disease if not 
readily diagnosed. Cerebral involvement is extremely rare and clinical presentation as 
hemorrhagic stroke is even rarer. 
Case presentation 
A 58-year-old Caucasian man was admitted to our medical unit because of a computed 
tomography-diagnosed hemorrhagic stroke with right-sided hemiparesis and fever. A chest 
computed tomography scan also revealed multiple bilateral pulmonary infiltrates; coronary 
artery, and carotid and left vertebral artery calcifications were also observed. Empiric 
antimicrobial therapy with cephalosporins was promptly undertaken; low-molecular-weight 
heparin was introduced as prophylaxis for venous thromboembolism. Over the following 
days, magnetic resonance imaging scans showed a regression of the hemorrhagic framework, 
also revealing hypoxic areas consistent with acute ischemic lesions. With a computed 
tomography scan showing a worsening of his pulmonary framework, antimicrobial therapy 
was modified and corticosteroids were introduced. A new blood cell count revealed further 
increased leukocytosis (17.49×103µL), characterized by a surprising rise of eosinophilic cells 
(32.8%). Angiography of the coronary arteries found diffuse dilatations with severe signs of 
endothelial damage. Such an unexpected framework induced a strong suspicion that the 
stroke was the expression of a systemic vasculitis, which had triggered his cerebral, coronary, 
and pulmonary frameworks. The search for antineutrophil cytoplasmic antibody was positive 
for perinuclear antineutrophil cytoplasmic antibody, and eosinophilic granulomatosis with 
polyangiitis was diagnosed. Explaining to the patient the rarity of his disease, and what the 
most typical presentations of eosinophilic granulomatosis with polyangiitis were, he revealed 
that before admission he had had scalp injuries, in the nuchal region, and had taken 
corticosteroids as self-medication, with subsequent disappearance of the lesions. Therefore, 
high-dose corticosteroid treatment was started, and at discharge he was in good clinical 
condition with a slight right-sided hyposthenia. 
Conclusions 
A diagnosis of eosinophilic granulomatosis with polyangiitis is often difficult, but we are 
convinced that intake of corticosteroids on a self-prescribed basis may have obscured the 
clinical presentation. Therefore, this case also suggests how the growing phenomenon of self-
medication can be harmful, and that a careful investigation of clinical history is still an act of 
paramount importance. 
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Introduction 
Churg–Strauss syndrome or, as recently renamed, eosinophilic granulomatosis with 
polyangiitis (EGPA) [1], is a rare and potentially fatal disease, with an annual incidence 
ranging between 0.5 and 6.8 per million, and a prevalence of 10.7 to 14 per million [2]. This 
condition is defined by the presence of eosinophil-rich and necrotizing granulomatous 
inflammation, often involving the respiratory tract, and necrotizing vasculitis primarily 
affecting the small to medium vessels. Asthma and eosinophilia are highly associated with 
EGPA, and nasal polyps are common. Antineutrophil cytoplasmic antibodies (ANCAs) are 
frequent, particularly when glomerulonephritis is present [3]. Neurological involvement as 
peripheral neuropathy is a common feature, whereas cerebral involvement is extremely rare. 
We present a case of an adult male athlete admitted for hemorrhagic stroke whose final 
diagnosis was EGPA. 
Case presentation 
In mid-August 2013, a 58-year-old Caucasian man was admitted to our medical unit because 
of a hemorrhagic stroke with right-sided hemiparesis and fever. He was married and had two 
sons, had been employed at an electrical company, and had recently retired. He was an 
amateur marathon runner, covering about 5000km annually. The previous April he had taken 
part in a half-marathon, finishing fifth. His medical history was negative for cardiac 
symptoms or metabolic diseases. He had undergone a nasal polypectomy 7 years earlier and 
occasionally suffered from rhinitis and mild asthma, using low to middle doses of 
corticosteroids (prednisone 12.5 to 25mg per day) in periods of exacerbation on a self-
prescribed basis. A neurological examination showed right-sided hemiparesis, particularly of 
his lower limb. He complained of tension headaches and an inability to maintain a standing 
posture. In the emergency area, a head computed tomography (CT) scan showed spontaneous 
hyperdensity of a hemorrhagic nature within his cisternal space adjacent to his medulla and 
the interpeduncular cistern; small hypoxic areas in his left corona radiata and insula were also 
reported (Figure 1A, B). A chest CT scan (Figure 2) also revealed multiple bilateral 
pulmonary infiltrates with ground-glass appearance localized in the apex of both upper lobes, 
in the posterior segment of the right upper lobe, and in the posterior basal segment of the 
right lower lobe. Surprisingly, calcifications in his coronary artery, and his carotid and left 
vertebral arteries, were also observed. On admission, laboratory tests revealed the presence of 
increased serum concentrations of inflammatory markers (C-reactive protein 7.85mg/dL, 
erythrocyte sedimentation rate 35mm/hour) and leukocytosis (13.84103µL white blood cells, 
WBC) with neutrophilia (9.62×103µL, 80.5%). Because of the pulmonary framework, 
empiric antimicrobial therapy with cephalosporins (ceftazidime 6g/day intravenous) was 
promptly undertaken. Given the immobilization, and as prophylaxis for venous 
thromboembolism, low-molecular-weight heparin (LMWH) was introduced. Over the 
following days, several head CT scans showed a regression of the hemorrhagic framework, 
and confirmed the hypoxic areas in his left corona radiata and insula consistent with acute 
ischemic lesion (Figure 1C). The latter finding was confirmed by head magnetic resonance 
imaging (MRI; Figure 1D) and magnetic resonance angiography, showing a hematic effusion 
within the lateral ventricles on a fluid attenuated inversion recovery sequence and, moreover, 
several punctiform ischemic lesions predominantly sided in the subcortical areas of his 
cerebral hemispheres, and another ischemic lesion in correspondence to the corona radiata 
and the insula. Intracranial vascular malformations and other abnormalities were excluded. 
Subsequently, a chest CT scan showed a worsening of the pulmonary framework. As a result, 
antimicrobial therapy was modified with the introduction of teicoplanin plus levofloxacin and 
corticosteroids (betamethasone 4mg/day intravenous). A new blood cell count revealed 
increased values of inflammatory markers with leukocytosis (17.49×103µL WBC), 
characterized by a surprising rise in eosinophilic cells to 5.7×103µL (32.8%). Furthermore, 
high levels of serum immunoglobulin E (3721mg/dL) were found. Because of the minute 
ischemic lesions revealed by head MRI, and to rule out a cardiogenic thromboembolism, on 
the 6th day ultrasonic cardiography was done, but was negative. The day after, angiography 
was performed in order to exclude supra-aortic vessels thrombosis and coronary disease 
because the previous chest CT scan had revealed the presence of coronary calcifications (the 
electrocardiogram was normal). The supra-aortic vessels were free of relevant lesions but, 
surprisingly, the coronary arteries had diffuse dilatations and stenosis with severe signs of 
endothelial damage. In particular, angiography demonstrated extensive and severe parietal 
alterations throughout the course of the left coronary artery, obstructed at the end of the 
second section, extensive and severe parietal alterations of the left circumflex artery with 
moderate distal stenosis. (Figure 3A) and right coronary artery critical stenosis with diffuse 
and severe alterations throughout its course (Figure 3B). Such an unexpected framework of 
endothelial damage induced a strong suspicion that the stroke was the expression of a 
systemic vasculitis, which had triggered the cerebral, coronary, and pulmonary frameworks. 
The further increase in circulating eosinophil cells (42.6%, 7.4×103µL) led us to search for 
ANCA, which was positive for perinuclear-ANCA (p-ANCA; 1:200; reference value <1:20). 
A peripheral blood smear showed no presence of circulating blast cells. 
Figure 1 Initial non-contrast head computed tomography scan shows subarachnoid 
hemorrhage (arrows) (A, B); subsequent scan (C) shows ischemic lesion (arrow) that 
diffusion-weighted magnetic resonance imaging (D) confirms to be consistent with acute 
infarct. 
Figure 2 Non-contrast chest computed tomography scan shows multiple bilateral 
pulmonary infiltrates with ground-glass appearance. 
Figure 3 Angiography of left, circumflex (A) and right (B) coronary artery. 
A bone marrow aspiration was done to exclude a lymphoproliferative disorder, and revealed 
an increase in eosinophilic granulocytic series, with normal morphology in all stages of 
growth (Figure 4). A search for the Abr/Bcl gene was negative. A nasal mucus membrane 
biopsy showed no significant alterations. Urinary sediment analysis resulted in no relevant 
findings, nor did a renal artery ultrasonography examination or the indirect evaluation of 
intrarenal resistances (intrarenal resistance index and pulsatility index). 
Figure 4 Bone marrow biopsy shows an increase of eosinophils with normal maturation 
(Giemsa, 200×). 
With reference to the American College of Rheumatology criteria [4] (Table 1), and because 
of the concomitance of pulmonary infiltrates, central nervous system involvement, blood 
eosinophilia, prior history of pulmonary asthma and nasal polyposis, and p-ANCA positivity, 
EGPA was diagnosed. Explaining to the patient the rarity of his disease, and what the most 
typical presentations of EGPA were, he revealed that because of the onset of scalp injuries in 
the nuchal region he had taken prednisone 12.5mg as self-medication for the 5 days 
preceding admission, with the disappearance of the lesions. Therefore, high-dose 
corticosteroid treatment was started (prednisone 1mg/kg per day), with a prompt regression 
of blood eosinophilia and respiratory symptoms, another factor supporting our diagnosis. He 
was discharged after 22 days of hospitalization, in good clinical condition, able to ambulate, 
and with a slight right-sided hyposthenia. As regards his follow-up, it was done on an out-
patient basis at our department, with the aim of gradually reducing the corticosteroid dose, 
and tapering it to the maintenance dose. Two months after discharge, he was still in good 
clinical condition: the neurological impairment was greatly reduced and consisted only of a 
slight right-sided hyposthenia of his lower limb. There were no respiratory or cardiovascular 
symptoms, his WBC count was normal, and our advice was to remain under our observation 
for at least 2 years. 
Table 1 Churg–Strauss syndrome (The American College of Rheumatology 1990 
diagnostic criteria [4]) 
Asthma History of wheezing or diffuse high-pitched expiratory rhonchi 
Eosinophilia Eosinophilia >10% on differential white blood cell count 
Mono- or polyneuropathy Development of mononeuropathy, multiple mononeuropathies, or 
polyneuropathy (glove/stocking distribution) attributable to 
systemic vasculitis 
Pulmonary infiltrates, non-
fixed 
Migratory or transitory pulmonary infiltrates (not including fixed 
infiltrates) attributable to vasculitis 
Paranasal sinus 
abnormality 
History of acute or chronic paranasal sinus pain or tenderness or 
radiographic opacification of the paranasal sinuses 
Extravascular eosinophils Extravascular areas 
The presence of any four or more of the six criteria yields a sensitivity of 85% and a 
specificity of 99.7%. 
Discussion 
EGPA, also known as Churg–Strauss Syndrome [1], is a small vessel ANCA-associated 
vasculitis typically characterized by the triad asthma, eosinophilia and vasculitis. 
Alternatively, EGPA is described as having three progressive phases, namely, a prodromal 
“allergic/atopic” phase of asthma and rhinosinusitis [5], an eosinophilic phase in which 
eosinophil-rich inflammatory tissue infiltrates develop, and a vasculitic phase the 
manifestations of which are similar to other ANCA-associated vasculitides, such as palpable 
purpura or mononeuritis multiplex. In a 32-year study of 96 patients with EGPA, asthma was 
the most common presentation, followed by mononeuritis, whereas stroke was an infrequent 
symptom [6]. Asthma in EGPA occurs in almost all cases (>95%), often severe and requiring 
steroids, anticipating by several years (7 to 8 years on average) the onset of the vasculitic 
phase. Upper airway involvement occurs in 70 to 90% of cases in the form of a rhinosinusitis, 
often in the presence of nasal polyposis. Pulmonary involvement (70 to 90%) consists of 
irregular, migratory and bilateral infiltrates with areas of ground-glass appearance. 
Extrapulmonary manifestations can include constitutional symptoms (50 to 90%), 
musculoskeletal (50%) or cutaneous disease (40 to 70%), peripheral nervous system (>50%), 
cardiac (30 to 50%) and gastrointestinal (30 to 50%) involvement. Many patients with EGPA 
do not have glomerulonephritis. Of interest, only 25% of patients with EGPA who have no 
renal disease are ANCA-positive, whereas 75% with any renal disease, and 100% with 
documented necrotizing glomerulonephritis, have ANCA positivity [3]. Significant ANCA 
serum concentrations are found in approximately 40% of patients with EGPA, and most of 
these patients are p-ANCA positive (anti-myeloperoxidase antibodies) [7]. 
We faced some difficulties in the approach to this clinical case. First, cerebral involvement is 
extremely rare. Indeed, the onset characterized by hemorrhagic stroke is absolutely atypical, 
and even more so when thrombotic findings are subsequently discovered. Recently, Go et al. 
[8] reported two clinical cases of EGPA with subarachnoid hemorrhage and intracerebral 
hemorrhage, respectively, and according to their review of the literature only 11 other cases 
of intracranial hemorrhage in association with EGPA had been reported. Second, the typical 
EGPA cutaneous manifestations were absent. Furthermore, there was no blood eosinophilia 
on admission. Despite the fact that a unique EGPA pathognomonic framework has yet to be 
described in the literature, we are convinced that intake of corticosteroids on a self-prescribed 
basis in the days immediately preceding the appearance of neurological symptoms may have 
obscured the clinical presentation. Therefore, this case suggests how the growing 
phenomenon of self-medication [9] can sometimes be harmful [10]. 
Certainly, the picture revealed by head MRI, with a hemorrhagic and multiple, small, left-
side hypoxic areas, raised a strong suspicion that this was not a typical stroke. The 
progressive increase in eosinophils and pulmonary infiltrates, and the prior history of asthma 
and nasal polyposis, were important in arriving at a diagnosis. Of note secondary importance 
was the coronarographic response, which showed a diffuse and severe picture of endothelial 
damage, a further unmistakable sign of a systemic vasculitis. With this evidence, bone 
marrow aspiration seemed unnecessary. However, we decided to carry out this examination 
when the diagnosis was still uncertain and, given the complex spectrum of disorders related 
to serum eosinophilia [11], we had to exclude clonal disorders. 
Univocal consensus on treatment of EGPA is still lacking, although, certainly, any 
therapeutic approach must be strictly related to the disease. Different scores are available to 
this purpose. In our case, the Birmingham Vasculitis Activity Score [12], the “five-factors 
score” of the French Vasculitis Study Group [13], and the European League Against 
Rheumatism guidelines [14], would have recommended inducing remission with 
immunosuppressants, such as cyclophosphamide, in addition to corticosteroids. However, 
given the prompt and favorable clinical response to high-dose corticosteroids in this specific 
case, we decided not to use immunosuppressants, unless first-line corticosteroid therapy 
failed. However, this is an already recognized clinical approach [15]. In any event, even when 
the diagnosis was still far from definitive, we gave the patient LMWH as thromboembolic 
prophylaxis. In addition, a low dosage of corticosteroids was promptly started because of the 
pulmonary picture. Given the definitive diagnosis, this therapeutic approach worked, 
although we did not know it would at the time. Minimum sequelae were detectable at 
discharge, and he was found in even better condition at subsequent follow-up visits. 
However, we remain convinced that the positive outcome of this case was fortunate because 
we began treatment without a definitive diagnosis, and that prompt treatment of the 
immediate clinical picture was paramount in resolving our patient’s condition. 
Conclusions 
A diagnosis of EGPA is often difficult, but we are convinced that intake of corticosteroids on 
a self-prescribed basis may have mystified the clinical presentation. Therefore, this case also 
suggests how the growing phenomenon of self-medication can be harmful, and that a careful 
investigation of clinical history is still an act of paramount importance. 
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